Respiratory Tract Disease clinical trials at University of California Health

4 in progress, 1 open to eligible people

Showing trials for

  • Ralinepag to Improve Treatment Outcomes in PAH Patients

    open to eligible people ages 18 years and up

    Study ROR-PH-301, ADVANCE OUTCOMES, is designed to assess the efficacy and safety of ralinepag when added to pulmonary arterial hypertension (PAH) standard of care or PAH-specific background therapy in subjects with World Health Organization (WHO) Group 1 PAH.

    at UC Davis UC Irvine UCLA UCSD

  • (SYMPHONY) Phase 1/2 Study Targeting EGFR Resistance Mechanisms in NSCLC

    Sorry, in progress, not accepting new patients

    This is a Phase 1/2, open-label, first-in-human (FIH) study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and anticancer activity of BLU-945, a selective EGFR inhibitor, as monotherapy or in combination with osimertinib.

    at UC Irvine UCSD

  • Long-Term Efficacy and Safety of Ralinepag in Subjects With PAH Via an Open-Label Extension

    Sorry, accepting new patients by invitation only

    Study ROR-PH-303, ADVANCE EXTENSION, is an open-label extension (OLE) study for participants with WHO Group 1 PAH who have participated in another Phase 2 or Phase 3 study of ralinepag.

    at UC Davis UC Irvine UCLA UCSD

  • Real World Registry for Use of the Ion Endoluminal System

    Sorry, not currently recruiting here

    The primary objective of this study is to evaluate the performance of the Ion Endoluminal System with real-world use for pulmonary lesion localization or biopsy.

    at UC Davis

Our lead scientists for Respiratory Tract Disease research studies include .

Last updated: